GIN-CRC-Pareto: A graph-based Pareto-optimal multi-task learning framework to identify miRNA-target interactions in colorectal cancer

GIN-CRC-Pareto:一种基于图的帕累托最优多任务学习框架,用于识别结直肠癌中的miRNA-靶标相互作用

阅读:1

Abstract

Colorectal cancer (CRC) ranks as the third highest incidence among malignancies in humans and the second most common cause of cancer-related mortality in the United States. Accumulating evidence has established microRNAs (miRNAs) as critical regulators of cancer development and therapeutic response. Understanding miRNA-mRNA interactions is critical for elucidating the molecular mechanisms driving CRC and other malignancies. In this study, we proposed GIN-CRC-Pareto, a graph-based, Pareto-optimal multi-task learning framework that simultaneously predicts miRNA-mRNA binding pairs, identifies seed match pairings, and classifies seed match subtypes. By leveraging the power of graph neural networks and Pareto-optimal gradient balancing strategy, GIN-CRC-Pareto dynamically adjusted the task weights during training to optimize each task without compromising the others. Experimental results demonstrated that our framework consistently outperforms traditional deep learning models and existing state-of-the-art tools across multiple evaluation metrics, with 0.909 in accuracy, 0.909 in precision and 0.968 in AUC in the miRNA-mRNA binding pairs prediction task. Additionally, we further validated the generalizability of the framework in combination with transfer learning techniques to identify miRNA-target interactions across other cancers. These findings highlight the effectiveness of the proposed framework to comprehensively identify the miRNA-target interactions in CRC, with the potential to serve as a scalable and generalizable tool across diverse cancer types, ultimately facilitating the development of miRNA-based therapeutics for cancer treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。